Brief: IRLAB Secures Full Ownership Of Mesdopetam Project, Continues Product Development

IRLAB Therapeutics AB

21/08/2023 13:37

Aug 21 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB SECURES FULL OWNERSHIP OF MESDOPETAM PROJECT AND
CONTINUES
PRODUCT DEVELOPMENT
    * IRLAB THERAPEUTICS AB, A COMPANY DISCOVERING AND
DEVELOPING
NOVEL TREATMENTS FOR PARKINSON'S DISEASE, TODAY ANNOUNCED
TRANSFER OF RIGHTS FOR NOW PHASE III-READY MESDOPETAM PROJECT TO
IRLAB
    * IRLAB NOW HAS SECURED FULL OWNERSHIP OF MESDOPETAM PROJECT
INCLUDING, INTER ALIA, ALL TECHNOLOGY, RIGHTS, KNOW-HOW,
INTELLECTUAL PROPERTIES, AND MATERIALS, AND WILL CONTROL FURTHER
CLINICAL DEVELOPMENT AND FUTURE COMMERCIALIZATION
    * AS COMPENSATION, IRLAB WILL PAY IPSEN A LOW SINGLE-DIGIT
ROYALTY
BASED ON FUTURE PRODUCT SALES
    * IRLAB AND ITS ADVISORS, WITH IPSEN'S SUPPORT, ARE NOW
PREPARING
FOR AN END-OF-PHASE 2 MEETING WITH FDA AS PART OF DETAILED
PLANNING FOR PHASE III
    * ALL TECHNICAL ASPECTS IN PREPARATION OF MESDOPETAM FOR
PHASE III
WERE COMPLETED DURING IRLAB/IPSEN COLLABORATION

Source text for Eikon:  ID:nMFN9wYwsR 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))